汕头大学医学院附属医院
Shantou University Medical College hospitals
在本站收录的 53 种疾病中,这家医院列在其中 15 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。
这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。
这家医院的官网还没有核对。
汕头大学医学院附属医院的研究
选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。
只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出
- 鼻咽癌Nasopharyngeal carcinoma8 篇牵头论文
- 食管鳞状细胞癌Oesophageal squamous cell carcinoma66 篇牵头论文牵头 2 项开放试验
- 肝细胞癌Hepatocellular carcinoma25 篇牵头论文
- 胃癌Stomach cancer26 篇牵头论文
- 肝母细胞瘤Hepatoblastoma0 篇牵头论文
- 骨肉瘤Osteosarcoma9 篇牵头论文
- β 地中海贫血Beta thalassaemia3 篇牵头论文
- 血友病 AHaemophilia A0 篇牵头论文
- 胆道闭锁Biliary atresia0 篇牵头论文
- 肝包虫病Hepatic echinococcosis1 篇牵头论文
- 特发性肺纤维化Idiopathic pulmonary fibrosis2 篇牵头论文
- 肺淋巴管平滑肌瘤病Lymphangioleiomyomatosis1 篇牵头论文
- 肌萎缩侧索硬化症Amyotrophic lateral sclerosis1 篇牵头论文
- IgA 肾病IgA nephropathy2 篇牵头论文
- 成骨不全症Osteogenesis imperfecta0 篇牵头论文
未列出的收录疾病:视网膜母细胞瘤、脊索瘤、胃肠道间质瘤、神经母细胞瘤、尤文肉瘤、多发性骨髓瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、范可尼贫血、视神经脊髓炎谱系疾病、IgG4相关性疾病、重症肌无力、烟雾病、肝豆状核变性、抗 NMDA 受体脑炎、大动脉炎、脊髓性肌萎缩症、法布雷病、庞贝病、杜氏肌营养不良、白塞病、Alport 综合征、戈谢病、尼曼-匹克病 C 型、原发性胆汁性胆管炎、原发性硬化性胆管炎、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、家族性腺瘤性息肉病、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。
癌症
鼻咽癌
Nasopharyngeal carcinoma2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 8 篇,占 0.3%。
- 牵头的开放试验
- 0
- 正在或即将招募
汕头有 1 家医院列在鼻咽癌下全国有 176 家医院列在鼻咽癌下
这家医院参与的开放试验 5
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募喉咽清口服液防治鼻咽癌放射性口腔黏膜炎Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid
- 分期
- III期
- 开始
- 2025-12
- 登记号
- NCT07311772
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 16 家列出的医院为研究中心上海、北京、南宁、常州、广州、成都、昆明、杭州、梧州、汕头、珠海、福州、长沙
- 正在招募Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy
- 分期
- III期
- 开始
- 2025-11
- 登记号
- NCT07328841
年龄 18 岁 至 70 岁(登记的条件)
牵头方不是列出的医院;另有 10 家列出的医院为研究中心中山、南宁、广州、梧州、武汉、汕头、珠海、长沙
- 正在招募40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma
- 分期
- III期
- 开始
- 2025-11
- 登记号
- NCT07328854
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 14 家列出的医院为研究中心中山、南宁、广州、成都、昆明、杭州、梧州、汕头、珠海、福州、长沙
- 正在招募Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
- 分期
- III期
- 开始
- 2024-03
- 登记号
- NCT06239727
年龄 18 岁 至 65 岁(登记的条件)
牵头:中山大学肿瘤防治中心;另有 21 家列出的医院为研究中心东莞、佛山、南京、南宁、南昌、厦门、天津、广州、成都、杭州、武汉、汕头、海口、湛江、福州、西安、贵阳、重庆、长沙
- 正在招募GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma
- 分期
- II期
- 开始
- 2024-06
- 登记号
- NCT06455410
年龄 18 岁 至 65 岁(登记的条件)
牵头:中山大学孙逸仙纪念医院;另有 7 家列出的医院为研究中心佛山、南宁、广州、柳州、汕头、深圳
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。卡片标题如有中文,为 AI 生成的译文,英文原文附后。
这些数字背后的记录
牵头的论文8
- Adiponectin Receptor 1-vascular endothelial growth factor axis mediates resistance to epidermal growth factor receptor-targeted therapy in nasopharyngeal carcinoma.
- Nasal irrigation reduces radiation-induced rhinosinusitis in nasopharyngeal carcinoma treated with volumetric modulated arc therapy.
- Comparing Flaps and Artificial Dermis for Skull Base Osteoradionecrosis Repair in Nasopharyngeal Carcinoma.
- A contrast-enhanced CT radiomics-based model to identify candidates for deintensified chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma patients.
- CPVL suppresses metastasis of nasopharyngeal carcinoma through inhibiting epithelial-mesenchymal transition.
- Autoantibody Signatures as a Biomarker Panel for the Detection of Nasopharyngeal Carcinoma.
- Sequential induction chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: the three-year report of a phase II, single center, randomized, non-inferiority
- Research status and prospects of biomarkers for nasopharyngeal carcinoma in the era of high‑throughput omics (Review).
它在 ClinicalTrials.gov 上的全部试验(任何状态)12
- Triple Antiemetic Regimen for Chemoradiotherapy in Cervical Cancer or Nasopharyngeal Cancer
- Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid
- Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy
- 40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma
- Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
- GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma
- Reduced-dose vs Standard-dose Irradiation for Low-risk Clinical Target Volume in Nasopharyngeal Carcinoma.
- A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma
- A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
- Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC)
- The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal Cancer
- The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC
PubMed 以外找到的论文(未计入)9
- 669MO Long term overall survival follow-up of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma
- Abstract CT011: Penpulimab versus placebo in combination with chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A global, multicenter, randomized, double-blind, phase 3 trial (AK105-304)
- Four-year overall survival follow-up and dynamic EBV titer analysis of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (r/m NPC).
- 860MO MRG003: A novel EGFR-targeted antibody-drug conjugant (ADC) for recurrent/metastatic nasopharyngeal carcinoma
- Final overall survival analysis of JUPITER-02: A phase 3 study of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).
- A Radiomics-Based Model to Identify Candidates for De-Intensified Treatment in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma
- Abstract CT226: Final progression-free survival analysis of JUPITER-02, a randomized, double-blind, phase 3 study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal ca
- 909P A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy: Updated results
- JUPITER-02: Randomized, double-blind, phase III study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).
癌症
食管鳞状细胞癌
Oesophageal squamous cell carcinoma2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 66 篇,占 2.3%。
汕头有 2 家医院列在食管鳞状细胞癌下全国有 191 家医院列在食管鳞状细胞癌下
这家医院参与的开放试验 5
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma
- 分期
- II期
- 开始
- 2025-12
- 登记号
- NCT07339488
年龄 18 岁 至 75 岁(登记的条件)
牵头:汕头大学医学院附属医院汕头
- 正在招募Adjuvant Chemotherapy in Combination With Tislelizumab in Lymph Node-Positive Esophageal Squamous Cell Carcinoma
- 分期
- I期
- 开始
- 2023-08
- 登记号
- NCT05984342
年龄 18 岁 至 70 岁(登记的条件)
牵头:汕头大学医学院附属医院汕头
- 正在招募SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
- 分期
- II期
- 开始
- 2026-08
- 登记号
- NCT07700667
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 19 家列出的医院为研究中心南京、南宁、南昌、哈尔滨、天津、太原、成都、昆明、汕头、沈阳、洛阳、石家庄、福州、西安、郑州、长春
- 正在招募A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
- 分期
- III期
- 开始
- 2025-03
- 登记号
- NCT06644781
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 28 家列出的医院为研究中心临沂、北京、南宁、厦门、合肥、哈尔滨、天津、安阳、成都、扬州、新乡、杭州、武汉、汕头、沈阳、洛阳、济南、济宁、福州、郑州、长春
- 正在招募Benmelstobart Combined With Radiochemotherapy as Neoadjuvant Treatment Iin ESCC
- 分期
- II期
- 开始
- 2024-10
- 登记号
- NCT06637163
年龄 18 岁 至 未注明(登记的条件)
牵头:复旦大学附属中山医院;另有 4 家列出的医院为研究中心上海、天津、杭州、汕头、沈阳
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文66
- Exploring solute carriers as biomarkers and therapeutic targets in esophageal squamous cell carcinoma.
- Interplay and cooperation between GLI2 and master transcription factors promote progression of esophageal squamous cell carcinoma.
- Machine learning technique-based four-autoantibody test for early detection of esophageal squamous cell carcinoma: a multicenter, retrospective study with a nested case-control study.
- Serum multiomics prediction of prognosis and adverse reactions to concurrent chemoradiotherapy in patients with esophageal cancer.
- Prognostic Value of Deep Learning-Extracted Tumor-Infiltrating Lymphocytes in Esophageal Cancer: A Multicenter Retrospective Cohort Study.
- Decoding epigenetic and transcriptional landscapes: DNA methylome-transcriptome integration reveals novel drivers in 4NQO-Induced esophageal squamous cell carcinoma mouse model.
- Increased IgG4 expression within tertiary lymphoid structures of esophageal cancer and implications for prognosis.
- Comprehensive analysis based on the ubiquitination- and deubiquitylation-related genes reveals the function of NEURL3 in esophageal squamous cell carcinoma.
- CXCL12-targeting siRNA nanoparticles alleviate immunosuppression and inhibit tumor progression in esophageal squamous cell carcinoma.
- Rho GAPase protein 1 (RACGAP1) affects the proliferation and metastasis of esophageal squamous cell carcinoma cells by regulating signaling pathways: Thermal infrared medical image inspection.
- Nuclear ANLN regulates transcription initiation related Pol II clustering and target gene expression.
- Transcriptomics-based analysis of key genes and potential mechanism and therapeutic agents in cadmium-induced esophageal squamous cell carcinoma progression.
- Esophageal cancer trends in the US from 1992 to 2019 with projections to 2044 using SEER data.
- Blood trace elements in association with esophageal squamous cell carcinoma risk, aggressiveness and prognosis in a high incidence region of China.
- Lympho-myeloid aggregate-infiltrating CD20+ B cells display a double-negative phenotype and correlate with poor prognosis in esophageal squamous cell carcinoma.
- Secreted proteins encoded by super enhancer-driven genes could be promising biomarkers for early detection of esophageal squamous cell carcinoma.
- Oncologic Outcome of Patients With Pathologic T0 Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemoradiotherapy.
- CPSF3 regulates alternative polyadenylation of CNIH2 to promote esophageal squamous cell carcinoma progression.
- Construction and validation of classification models for predicting the response to concurrent chemo-radiotherapy of patients with esophageal squamous cell carcinoma based on multi-omics data.
- EZH2 elicits CD8+ T-cell desert in esophageal squamous cell carcinoma via suppressing CXCL9 and dendritic cells.
- First-Line Tislelizumab for Advanced or Metastatic Esophageal Squamous Cell Carcinoma:A Cost-Effectiveness Analysis.
- Efficacy of the induced pluripotent stem cell derived and engineered CD276-targeted CAR-NK cells against human esophageal squamous cell carcinoma.
- Discovery and validation of combined biomarkers for the diagnosis of esophageal intraepithelial neoplasia and esophageal squamous cell carcinoma.
- Early Diagnostic Markers for Esophageal Squamous Cell Carcinoma: Copy Number Alteration Gene Identification and cfDNA Detection.
- NMR and MS reveal characteristic metabolome atlas and optimize esophageal squamous cell carcinoma early detection.
- Serine/threonine-protein kinase D2-mediated phosphorylation of DSG2 threonine 730 promotes esophageal squamous cell carcinoma progression.
- KAT8/SIRT7-mediated Fascin-K41 acetylation/deacetylation regulates tumor metastasis in esophageal squamous cell carcinoma.
- Nomogram based on pretreatment hepatic and renal function indicators for survival prediction of locally advanced esophageal squamous cell carcinoma with treatment of neoadjuvant chemoradiotherapy plus surgery.
- Development and Validation of a New Staging System for Esophageal Squamous Cell Carcinoma Patients Based on Combined Pathological TNM, Radiomics, and Proteomics.
- ASO Author Reflections: A Multiomic Novel Staging System for Esophageal Squamous Cell Carcinoma Patients.
- Relationship between esophageal squamous cell carcinoma risk and alcohol-related ALDH2 and ADH1B polymorphisms: Evidence from a meta-analysis and Mendelian randomization analysis.
- circSSPO boosts growth of esophageal squamous cell carcinoma through upregulation of micrRNA-6820-5p-mediated KLK8 and PKD1 expression.
- Targeting USP10 induces degradation of oncogenic ANLN in esophageal squamous cell carcinoma.
- Associations of trace element levels in paired serum, whole blood, and tissue: an example of esophageal squamous cell carcinoma.
- Economic evaluation of toripalimab plus chemotherapy compared with chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma in China.
- Evaluation of multiple immune cells and patient outcomes in esophageal squamous cell carcinoma.
- Comprehensive analysis of cuproptosis genes and cuproptosis-related genes as prognosis factors in esophageal squamous cell carcinoma.
- Cost-effectiveness analysis of serplulimab as first-line treatment for advanced esophageal squamous cell carcinoma.
- Different Expression Pattern of G Protein-Coupled Estrogen Receptor GPER1 in Esophageal Squamous Cell Carcinoma and Adenocarcinoma.
- Acetyl-CoA Acetyltransferase 2 Confers Radioresistance by Inhibiting Ferroptosis in Esophageal Squamous Cell Carcinoma.
- Spatial analysis of stromal signatures identifies invasive front carcinoma-associated fibroblasts as suppressors of anti-tumor immune response in esophageal cancer.
- The Preoperative Neutrophil to Lymphocyte Ratio Predicts Survival in Patients with Esophageal Squamous Cell Carcinoma: a Propensity Score Matching Analysis.
- CD22 is a potential target of CAR-NK cell therapy for esophageal squamous cell carcinoma.
- Prenylated PALM2 Promotes the Migration of Esophageal Squamous Cell Carcinoma Cells Through Activating Ezrin.
- A protein complex of LCN2, LOXL2 and MMP9 facilitates tumour metastasis in oesophageal cancer.
- Serum insulin-like growth factor binding protein-3 as a potential biomarker for diagnosis and prognosis of oesophageal squamous cell carcinoma.
- TRIP13 Induces Nedaplatin Resistance in Esophageal Squamous Cell Carcinoma by Enhancing Repair of DNA Damage and Inhibiting Apoptosis.
- Role of Cell-Cell Junctions in Oesophageal Squamous Cell Carcinoma.
- Serum DSG2 as a potential biomarker for diagnosis of esophageal squamous cell carcinoma and esophagogastric junction adenocarcinoma.
- Fascin lysine 471 acetylation cooperates with serine 39 phosphorylation to inhibit actin-bundling activity and tumor metastasis in esophageal squamous cell carcinoma.
- Blocking STAT3 signaling augments MEK/ERK inhibitor efficacy in esophageal squamous cell carcinoma.
- Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy vs. Chemotherapy Alone as First-Line Treatment in Patients With Esophageal Squamous Cell Carcinoma and PD-L1 CPS of 10 or More.
- Esophageal Squamous Cancer from 4NQO-Induced Mice Model: CNV Alterations.
- Potential Chemotherapeutic Effect of Selenium for Improved Canceration of Esophageal Cancer.
- PABPC1-induced stabilization of IFI27 mRNA promotes angiogenesis and malignant progression in esophageal squamous cell carcinoma through exosomal miRNA-21-5p.
- Anti-tumour effects of a macrolide analog F806 in oesophageal squamous cell carcinoma cells by targeting and promoting GLUT1 autolysosomal degradation.
- Surgical resection for esophageal adenosquamous carcinoma: an analysis of 56 cases.
- Promotion of rs3746804 (p. L267P) polymorphism to intracellular SLC52A3a trafficking and riboflavin transportation in esophageal cancer cells.
- P300/CBP-associated factor (PCAF)-mediated acetylation of Fascin at lysine 471 inhibits its actin-bundling activity and tumor metastasis in esophageal cancer.
- STAT3β disrupted mitochondrial electron transport chain enhances chemosensitivity by inducing pyroptosis in esophageal squamous cell carcinoma.
- Identification and Validation of Esophageal Squamous Cell Carcinoma Targets for Fluorescence Molecular Endoscopy.
- Systematic Proteome and Lysine Succinylome Analysis Reveals Enhanced Cell Migration by Hyposuccinylation in Esophageal Squamous Cell Carcinoma.
- The miR-19b-3p-MAP2K3-STAT3 feedback loop regulates cell proliferation and invasion in esophageal squamous cell carcinoma.
- Integrated single-cell transcriptome analysis reveals heterogeneity of esophageal squamous cell carcinoma microenvironment.
- CircDUSP16 Contributes to Cell Development in Esophageal Squamous Cell Carcinoma by Regulating miR-497-5p/TKTL1 Axis.
- linc01305 promotes metastasis and proliferation of esophageal squamous cell carcinoma through interacting with IGF2BP2 and IGF2BP3 to stabilize HTR3A mRNA.
它在 ClinicalTrials.gov 上的全部试验(任何状态)19
- Adjuvant Chemotherapy in Combination With Tislelizumab in Lymph Node-Positive Esophageal Squamous Cell Carcinoma
- Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma
- Study of Simultaneous Modulated Accelerated Radiation Therapy Concurrent With Chemotherapy to Treat Esophageal Cancer
- SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
- A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
- Benmelstobart Combined With Radiochemotherapy as Neoadjuvant Treatment Iin ESCC
- Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma
- Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
- Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
- A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy
- A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma
- Performance of White Light, NBI and Iodine Staining Endoscopy in the Diagnosis of Esophageal Lesions
- A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma
- A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
- A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
- The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC
- A Phase III Study of Nimotuzumab Plus Concurrent Chemoradiotherapy in Loco-regional Esophageal Squamous Cell Carcinoma
- Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell Carcinoma
- Phase III Study of Neo-adjuvant Chemoradiotherapy Followed by Surgery for Squamous Cell Esophageal Cancer
PubMed 以外找到的论文(未计入)11
- Long-Term Outcomes of Dose Escalation in Definitive Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter, Randomized Phase III Trial
- Global, randomized, phase III study of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced/metastatic esophageal squamous cell carcinoma (RATIONALE-306 update): Minimum 3-year survival follow
- 1514P Randomized, global, phase III study of tislelizumab (TIS) + chemotherapy (chemo) vs placebo (PBO) + chemo as first-line (1L) treatment for advanced/metastatic esophageal squamous cell carcinoma (ESCC): RATIONALE-306 update
- Abstract CT076: Randomized, global, phase 3 study of tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-306): China subgroup analysis
- 70O Randomized, global, phase III study of tislelizumab (TIS) + chemotherapy (chemo) vs chemo as first-line (1L) therapy for advanced or metastatic esophageal squamous cell carcinoma (ESCC) (RATIONALE-306): Asia subgroup
- ASO Visual Abstract: Combined Mean Corpuscular Hemoglobin, Fibrinogen, and Albumin (MF-A) Is a Novel Prognostic Marker in Patients with Resectable Esophageal Squamous Cell Carcinoma
- Additional file 1 of PABPC1-induced stabilization of IFI27 mRNA promotes angiogenesis and malignant progression in esophageal squamous cell carcinoma through exosomal miRNA-21-5p
- LBA-1 RATIONALE-306: Randomized, global, placebo-controlled, double-blind phase 3 study of tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC)
- Relationship between esophageal squamous cell carcinoma risk and ALDH2 and ADH1B polymorphisms:Evidence from a Meta-Analysis
- Corrigendum: TRPC1 Inhibits Cell Proliferation/Invasion and Is Predictive of a Better Prognosis of Esophageal Squamous Cell Carcinoma
- Decreased Average Albumin-to-Globulin Ratio During Radiotherapy Worsens the Prognosis of Esophageal Squamous Cell Carcinoma: Implications for Nutritional Management
癌症
肝细胞癌
Hepatocellular carcinoma2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 25 篇,占 0.2%。
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
汕头有 1 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的肝细胞癌开放试验。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文25
- Crippled Hepatocarcinogenesis Inhibition of Quercetin in Glycolysis Pathway with Hepatic Farnesoid X Receptor Deficiency.
- Exosomal ETV4 Derived From M2 Macrophages Induces Growth, Glycolysis and Stemness in Hepatocellular Carcinoma by UpRegulating SULT2B1 Expression.
- Integrated multiomics analysis highlights the immunosuppressive role of granulin precursor positive macrophages in hepatocellular carcinoma.
- Unsupervised Clustering Subtype Analysis and Prognostic Risk Model of Cuproptosis-Related Genes for Liver Cancer.
- AFB1 consolidates HBV harm to induce liver injury and carcinogenic risk by inactivating FTCD-AS1-PXR-MASP1 axis.
- Human endogenous retrovirus ERVK3-1 characterizes a metabolically active and immunosuppressive subtype of liver cancer.
- The Intrinsic Innate Immunity of Hepatocytes Suppresses HBV Replication and Is Antagonized by HBx.
- Comparative analysis of the performance of hepatobiliary agents in depicting MRI features of microvascular infiltration in hepatocellular carcinoma.
- Camrelizumab plus rivoceranib compared sorafenib as first-line therapeutic options for advanced hepatocellular carcinoma in China: a cost-effectiveness analysis.
- Tislelizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma in China: a cost-effectiveness analysis.
- Exosomal IGFBP2 derived from highly metastatic promotes hepatocellular carcinoma metastasis by inducing epithelial mesenchymal transition.
- MRTO4 Enhances Glycolysis to Facilitate HCC Progression by Inhibiting ALDOB.
- Improvement of rat hepatocellular carcinoma model induced by diethylnitrosamine.
- Expression Patterns of HOX Gene Family Defines Tumor Microenvironment and Immunotherapy in Hepatocellular Carcinoma.
- Disulfidptosis-related signatures for prognostic and immunotherapy reactivity evaluation in hepatocellular carcinoma.
- Circ_0031242 regulates the functional properties of hepatocellular carcinoma cells through the miR-944/MAD2L1 axis.
- The relationship between the efficacy of thermal ablation and inflammatory response and immune status in early hepatocellular carcinoma and the progress of postoperative adjuvant therapy.
- C-Terminal Truncated HBx Facilitates Oncogenesis by Modulating Cell Cycle and Glucose Metabolism in FXR-Deficient Hepatocellular Carcinoma.
- Hollow Mesoporous Silica Nanoparticles for Dual Chemo-starvation Therapy of Hepatocellular Carcinoma.
- The Prognostic and Immunotherapeutic Significance of AHSA1 in Pan-Cancer, and Its Relationship With the Proliferation and Metastasis of Hepatocellular Carcinoma.
- Purine-Induced IFN-γ Promotes Uric Acid Production by Upregulating Xanthine Oxidoreductase Expression.
- A novel prognostic signature based on four glycolysis-related genes predicts survival and clinical risk of hepatocellular carcinoma.
- Cooperation between liver-specific mutations of pten and tp53 genetically induces hepatocarcinogenesis in zebrafish.
- Combination of curcumin with N-n-butyl haloperidol iodide inhibits hepatocellular carcinoma malignant proliferation by downregulating enhancer of zeste homolog 2 (EZH2) - lncRNA H19 to silence Wnt/β-catenin signaling.
- Partial abrogation of FXR-KNG1 signaling by carboxyl-terminal truncated HBx-C30 in hepatitis B virus-associated hepatocellular carcinoma.
癌症
胃癌
Stomach cancer2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 26 篇,占 0.3%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
汕头有 1 家医院列在胃癌下全国有 218 家医院列在胃癌下
这家医院参与的开放试验 3
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
- 分期
- III期
- 开始
- 2026-04
- 登记号
- NCT07385703
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 62 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、南京、南充、南昌、厦门、合肥、天津、太原、安阳、常州、广州、徐州、成都、扬州、承德、昆明、杭州、武汉、汕头、沈阳、洛阳、济南、海口、石家庄、福州、苏州、西安、郑州、重庆、长春、长沙、青岛
- 正在招募Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
- 分期
- 未注明
- 开始
- 2025-02
- 登记号
- NCT06846996
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 31 家列出的医院为研究中心上海、北京、南京、台州、天津、太原、广州、徐州、杭州、汕头、沈阳、海口、福州、郑州、长春
- 正在招募OGT-assisted Overlap Esophagojejunostomy Versus Traditional Overlap Method
- 分期
- 不分期
- 开始
- 2022-09
- 登记号
- NCT05450835
年龄 18 岁 至 75 岁(登记的条件)
牵头:南方医科大学南方医院;另有 7 家列出的医院为研究中心广州、汕头、沈阳、长春、长沙
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文26
- Development and validation of the antibody-dependent cellular phagocytosis-based signature: A prognostic risk model of gastric cancer.
- Cost-effectiveness analysis of cadonilimab plus chemotherapy as a first-line treatment option in HER-2-negative advanced gastric cancer.
- Programmed cell death 1 inhibitor combined with chemotherapy compared to chemotherapy alone as first-line treatment in advanced gastric cancer patients: A real-world study.
- Sugemalimab plus chemotherapy versus chemotherapy for advanced gastric cancer in China: a cost-effectiveness analysis.
- Expression and prognostic value of APOBEC2 in gastric adenocarcinoma and its association with tumor-infiltrating immune cells.
- Genomic characteristics and evolution of Multicentric Esophageal and gastric Cardiac Cancer.
- Pembrolizumab combined with chemotherapy versus placebo combined with chemotherapy for HER2-negative advanced gastric cancer in China: a cost-effectiveness analysis.
- Identification and characterization of CLEC11A and its derived immune signature in gastric cancer.
- Genome-wide DNA methylation and transcriptomic patterns of precancerous gastric cardia lesions.
- OLFM4 promotes the progression of intestinal metaplasia through activation of the MYH9/GSK3β/β-catenin pathway.
- Machine learning based intratumor heterogeneity signature for predicting prognosis and immunotherapy benefit in stomach adenocarcinoma.
- Combined detection of serum EFNA1 and MMP13 as diagnostic biomarker for gastric cancer.
- Vonoprazan-based triple and dual therapy versus bismuth-based quadruple therapy for Helicobacter pylori infection in China: a three-arm, randomised clinical trial protocol.
- Immune checkpoint inhibitors and cellular immunotherapy for advanced gastric, gastroesophageal cancer: a long pathway.
- Grid2 interacting protein is a potential biomarker related to immune infiltration in colorectal cancer.
- Genome-wide DNA methylation profiling of gastric cardia cancer.
- Establishment and characterization of two Epstein-Barr virus-positive gastric cancer cell lines with epitheliotropic M81 strain undergoing distinct viral and altered cellular expression profiles.
- Epstein-Barr virus-encoded miR-BART11-3p modulates the DUSP6-MAPK axis to promote gastric cancer cell proliferation and metastasis.
- The diagnostic value of serum insulin-like growth factor binding protein 7 in gastric cancer.
- A novel 8-genome instability-associated lncRNAs signature predicting prognosis and drug sensitivity in gastric cancer.
- Circular RNA circ_0006089 promotes the progression of gastric cancer by regulating the miR-143-3p/PTBP3 axis and PI3K/AKT signaling pathway.
- Clinical correlations and prognostic value of Nudix hydroxylase 10 in patients with gastric cancer.
- Early B-cell factors involve in the tumorigenesis and predict the overall survival of gastric cancer.
- Serum CYR61 as a potential biomarker for the diagnosis of esophagogastric junction tumor.
- Lymph Node Ratio Is an Independent Prognostic Factor for Patients with Siewert Type II Adenocarcinoma of Esophagogastric Junction: Results from a 10-Year Follow-up Study.
- Accumulation of Nicotinamide N-Methyltransferase (NNMT) in Cancer-associated Fibroblasts: A Potential Prognostic and Predictive Biomarker for Gastric Carcinoma.
它在 ClinicalTrials.gov 上的全部试验(任何状态)11
- Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
- Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
- OGT-assisted Overlap Esophagojejunostomy Versus Traditional Overlap Method
- A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)
- Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
- Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.
- A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression
- A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer
- Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer
- The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC
- Compare S-1 Plus Oxaliplatin to S-1 as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer
癌症
肝母细胞瘤
Hepatoblastoma2021–2025 年没有牵头肝母细胞瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
汕头有 1 家医院列在肝母细胞瘤下全国有 88 家医院列在肝母细胞瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肝母细胞瘤开放试验。
癌症
骨肉瘤
Osteosarcoma2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 9 篇,占 0.4%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
汕头有 2 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文9
- Circ_0002669 promotes osteosarcoma tumorigenesis through directly binding to MYCBP and sponging miR-889-3p.
- CircPVT1 promotes migration and invasion by regulating miR-490-5p/HAVCR2 axis in osteosarcoma cells.
- A tumor suppressor protein encoded by circKEAP1 inhibits osteosarcoma cell stemness and metastasis by promoting vimentin proteasome degradation and activating anti-tumor immunity.
- LncRNA WAC-AS1 promotes osteosarcoma Metastasis and stemness by sponging miR-5047 to upregulate SOX2.
- The Influence of MDR1 Expression Regulated by miR-138 through TRPS1 Signaling Pathway on Multidrug Resistance of Osteosarcoma and Formation of Bacterial Infection Biofilm.
- PITX1 suppresses osteosarcoma metastasis through exosomal LINC00662-mediated M2 macrophage polarization.
- RAMP1 as a novel prognostic biomarker in pan-cancer and osteosarcoma.
- Hsa_circ_0001017 promotes cell proliferation, migration and invasion in osteosarcoma by sponging miR-145-5p.
- Oncogenic gene TRIM10 confers resistance to cisplatin in osteosarcoma cells and activates the NF-κB signaling pathway.
早期论文(2016–2020 年)3
- Cadmium chloride enhances cisplatin sensitivity in osteosarcoma cells by reducing FOXM1 expression.
- Phage display-derived oligopeptide-functionalized probes for in vivo specific photoacoustic imaging of osteosarcoma.
- MiR-19a regulates the cell growth and apoptosis of osteosarcoma stem cells by targeting PTEN.
血液疾病
β 地中海贫血
Beta thalassaemia2021–2025 年中国大陆作者发表的 312 篇β 地中海贫血 PubMed 英文论文中,这家医院牵头了 3 篇,占 1.0%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
汕头有 2 家医院列在β 地中海贫血下全国有 157 家医院列在β 地中海贫血下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的β 地中海贫血开放试验。
这些数字背后的记录
牵头的论文3
- AZD8055 Is More Effective Than Rapamycin in Inhibiting Proliferation and Promoting Mitochondrial Clearance in Erythroid Differentiation.
- The value of Mentzer index in the diagnosis of children thalassemia minor.
- Molecular characterization of hemoglobinopathies and thalassemias in Northern Guangdong Province, China.
血液疾病
血友病 A
Haemophilia A2021–2025 年没有牵头血友病 A的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
汕头有 1 家医院列在血友病 A下全国有 160 家医院列在血友病 A下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血友病 A开放试验。
其他疾病
胆道闭锁
Biliary atresia2021–2025 年没有牵头胆道闭锁的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
汕头有 1 家医院列在胆道闭锁下全国有 28 家医院列在胆道闭锁下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的胆道闭锁开放试验。
这些数字背后的记录
其他疾病
肝包虫病
Hepatic echinococcosis2021–2025 年中国大陆作者发表的 152 篇肝包虫病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.7%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
汕头有 1 家医院列在肝包虫病下全国有 49 家医院列在肝包虫病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肝包虫病开放试验。
其他疾病
特发性肺纤维化
Idiopathic pulmonary fibrosis2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.2%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
汕头有 1 家医院列在特发性肺纤维化下全国有 333 家医院列在特发性肺纤维化下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。
这些数字背后的记录
其他疾病
肺淋巴管平滑肌瘤病
Lymphangioleiomyomatosis2021–2025 年中国大陆作者发表的 45 篇肺淋巴管平滑肌瘤病 PubMed 英文论文中,这家医院牵头了 1 篇,占 2.2%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
汕头有 1 家医院列在肺淋巴管平滑肌瘤病下全国有 28 家医院列在肺淋巴管平滑肌瘤病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肺淋巴管平滑肌瘤病开放试验。
其他疾病
肌萎缩侧索硬化症
Amyotrophic lateral sclerosis2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
汕头有 1 家医院列在肌萎缩侧索硬化症下全国有 194 家医院列在肌萎缩侧索硬化症下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肌萎缩侧索硬化症开放试验。
其他疾病
IgA 肾病
IgA nephropathy2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.3%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
汕头有 3 家医院列在IgA 肾病下全国有 346 家医院列在IgA 肾病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。
其他疾病
成骨不全症
Osteogenesis imperfecta2021–2025 年没有牵头成骨不全症的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
汕头有 1 家医院列在成骨不全症下全国有 59 家医院列在成骨不全症下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的成骨不全症开放试验。
联系这家医院
出示给工作人员或司机的院名卡
汕头大学医学院附属医院
Shantou University Medical College hospitals
汕头
大医院往往有多个院区,出发前请先向医院确认院区。
中英对照的咨询信
填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。
医院通常需要的资料
- 主治医生近期的病情总结或信件
- 病理报告
- 影像检查(CT、MRI、PET)及报告,尽量附影像文件
- 已接受的治疗及时间
- 目前用药
下一步建议
这些数字从哪里来
论文
2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义
试验
ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。
编号与其他名称
ROR
Shantou University Medical College; Cancer Hospital of Shantou University Medical College; First Affiliated Hospital of Shantou University Medical College; Medical College of Shantou University; Affiliated Cancer Hospital of Shantou University Medical College; Second Affiliated Hospital of Shantou University Medical College; Shantou University; 汕头大学医学院附属肿瘤医院